Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, Tremelimumab, and Radiation in HCC and BTC
NCT03482102Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- May 2018
- Primary completion
- Feb 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in hepatocellular carcinoma (HCC), biliary tract cancer (BTC), sponsored by Massachusetts General Hospital. Started May 2018; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03482102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03482102.